1. Risk Management Plan (ISO 14971, Clause 4)
The plan defines the scope of work, the life cycle phases to be considered, responsibilities, methods, acceptance criteria, and interfaces. It serves as the binding steering document—not created retrospectively, but established as early as the concept phase. Metecon develops the risk management plan in collaboration with your development team so that it can be used immediately as a basis for decision-making.
2. Risk Analysis: Identifying Hazards (Clause 5)
Systematic identification of all (potential) relevant hazards across the entire product life cycle: known and foreseeable hazards, including misuse, hazardous situations, and damage scenarios. Methods such as FMEA, fault tree analysis (FTA), and hazard lists are selected on a product-specific basis. Metecon ensures that the risk analysis fully covers the characteristics of your product—including use-related risks from the usability assessment.
3. Risk Assessment with Product-Specific Acceptance Criteria (Clause 6)
Each identified risk is evaluated against the acceptance criteria specified in the plan. Important: The acceptance criteria must be justified on a product-specific basis—generic evaluation matrices often do not stand up to scrutiny in audits. Metecon supports you and works with you to develop acceptance criteria that are appropriate for the product class, clinical evidence, and state of the art.
4. Risk Control: Hierarchy of Measures (Clause 7)
ISO 14971 stipulates a clear hierarchy of risk-mitigation measures: (1) inherently safe design and safe manufacture, (2) protective measures in the medical device itself or in the manufacturing process, (3) safety information (IFU, warnings) and, where appropriate, training to the user. Information alone is rarely sufficient—measures at the first level of the hierarchy are preferred from a regulatory standpoint. Metecon provides support in risk mitigation.
5. Verification & Validation of Measures (Clause 7.3 + Clause 9)
Every risk-control measure must be verified. Verification of its effectiveness can be carried out as part of the V&V activities; traceability between the risk, the measure and the verification is mandatory. Metecon assists with the implementation of the necessary processes and documentation – ensuring everything is audit-ready.
6. Residual Risk Evaluation, Benefit-Risk Analysis, Completeness of Risk Control (Clause 7.3 - Clause 7.6)
Once the measures have been implemented, residual risks are assessed against the pre-defined acceptance criteria. In a benefit-risk analysis, the benefits of the intended purpose are weighed against the respective residual risk that does not meet the acceptance criteria. Furthermore, it must be reviewed whether the risk control measures taken have possibly introduced new hazards or hazardous situations, and whether other risks have been affected by them. The completion of these activities involves verifying whether risks arising from all identified hazard situations have been considered and whether all measures have been finalized – the results of the checks must be consistent. Metecon ensures the consistency between the various verification steps and activities.
7. Assessment of the Overall Residual Risk (Clause 8)
The overall residual risk posed by the medical device is assessed in relation to the benefits of its intended purpose and documented once all risk control measures have been implemented and verified. Information on acceptable residual risks must be disclosed in the accompanying documentation (instructions for use, IFU). The evaluation result must comply with the criteria set out in the risk management plan and be consistent with the assessment of the individual residual risks. Metecon ensures that all evaluation results are consistent and documented.
8. Risk Management Report (Clause 9)
Prior to the product’s market authorization, it is verified that the requirements of the risk management plan have been fully implemented, that the overall residual risk is acceptable, and that suitable methods have been put in place to collect and verify the information required by the regulatory authorities regarding the product’s safety and performance, both during and after manufacture – process monitoring and PMS. The results of this assessment are documented in a risk management report, which is part not only of the risk management file but also of the technical documentation. Metecon shows how the two files are linked.
9. Product Life Cycle: Production and Post-Production Information (Clause 10)
EN ISO 14971 requires that findings from production and post-market activities (PMS, PMCF/PMPF) are systematically fed back into the risk management process. Process interfaces and evaluation criteria must be defined for this purpose. Metecon links the risk management process and process monitoring activities with post-market surveillance (PMS) activities.
10. ISO/TR 24971:2020: Guidance on the Application of EN ISO 14971
The ISO/TR 24971 guidance elaborates on many aspects of EN ISO 14971 with examples, methods and recommendations, particularly regarding acceptance criteria, the selection of methods and interfaces with other processes. Metecon uses both the standard and the guidance to ensure efficient risk management.